# Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment

> **NCT00717990** · PHASE2 · TERMINATED · sponsor: **University Hospital of Crete** · enrollment: 15 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Bevacizumab
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT00717990
- **Lead sponsor:** University Hospital of Crete
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Poor Accrual
- **Last updated:** 2015-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00717990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00717990, "Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00717990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*